Lymphopenia and Early Variation of Lymphocytes to Predict In-Hospital Mortality and Severity in ED Patients with SARS-CoV-2 Infection
- PMID: 35407409
- PMCID: PMC8999889
- DOI: 10.3390/jcm11071803
Lymphopenia and Early Variation of Lymphocytes to Predict In-Hospital Mortality and Severity in ED Patients with SARS-CoV-2 Infection
Abstract
(1) Introduction: Multiple studies have demonstrated that lymphocyte count monitoring is a valuable prognostic tool for clinicians during inflammation. The aim of our study was to determine the prognostic value of delta lymphocyte H24 from admission from the emergency department for mortality and severity of SARS-CoV-2 infection. (2) Methods: We have made a retrospective and multicentric study in six major hospitals of northeastern France. The patients were hospitalized and had a confirmed diagnosis of SARS-CoV-2 infection. (3): Results: A total of 1035 patients were included in this study. Factors associated with infection severity were CRP > 100 mg/L (OR: 2.51, CI 95%: (1.40−3.71), p < 0.001) and lymphopenia < 800/mm3 (OR: 2.15, CI 95%: (1.42−3.27), p < 0.001). In multivariate analysis, delta lymphocytes H24 (i.e., the difference between lymphocytes values at H24 and upon admission to the ED) < 135 was one of the most significant biochemical factors associated with mortality (OR: 2.23, CI 95%: (1.23−4.05), p = 0.009). The most accurate threshold for delta lymphocytes H24 was 75 to predict severity and 135 for mortality. (4) Conclusion: Delta lymphocytes H24 could be a helpful early screening prognostic biomarker to predict severity and mortality associated with COVID-19.
Keywords: COVID-19; lymphopenia; mortality.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
References
-
- WHO Coronavirus (COVID-19) Dashboard. [(accessed on 30 December 2020)]. Available online: https://covid19.who.int.
-
- Gerotziafas G.T., Sergentanis T.N., Voiriot G., Lassel L., Papageorgiou C., Elabbadi A., Turpin M., Vandreden P., Papageorgiou L., Psaltopoulou T., et al. Derivation and Validation of a Predictive Score for Disease Worsening in Patients with COVID-19. Thromb. Haemost. 2020;120:1680–1690. doi: 10.1055/s-0040-1716544. - DOI - PMC - PubMed
-
- Linssen J., Ermens A., Berrevoets M., Seghezzi M., Previtali G., van der Sar-van der Brugge S., Russcher H., Verbon A., Gillis J., Riedl J., et al. A novel haemocytometric COVID-19 prognostic score developed and validated in an observational multicentre European hospital-based study. eLife. 2020;9:e63195. doi: 10.7554/elife.63195. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
